|
|
Microcap HeadlinesThe best kept secrets on Wall Street
Anavex Life Sciences Corp.
51 West 52nd Street
New York, New York 10019
BASIC INFORMATION
COMPANY HISTORY
Anavex Life Sciences Corp. is a Nevada corporation that was incorporated in 2006 and went public in January 2007 through a reverse merger. Since inception, the Company has worked to develop its products through a rigorous development process involving its proprietary SigmaCeptor(R) platform. The Company has developed several promising small molecule compounds targeting Alzheimer's disease other diseases of the Central Nervous Systems (CNS) and cancer.
COMPANY BUSINESS SUMMARY
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s disease, other CNS diseases, and various types of cancer.
ANAVEX 2-73, the Company’s orally available drug candidate with potential disease modification is currently in a Phase 2a clinical trial. Recent research shows that chronic stress in brain cells, a feature highly correlated with age causes protein misfolding. ANAVEX drug candidates target the mixed muscarinic/ Sigma 1-Receptor to reduce cell stress through calcium modulation, hence reducing inflammation, mitochondrial dysfunction, as well as reducing both A-beta and Tau.
ANAVEX 2-73 which has shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease has undergone a Phase 1 human clinical trial. No serious side effects were reported, and, there was no study discontinuation. ANAVEX 2-73 was found to be safe and well tolerated, and the results indicate a favorable pharmacokinetics profile suitable for once daily dosing.
An encouraging synergistic effect has been observed between ANAVEX2-73 and donepezil (Aricept®). The combined therapeutics, referred to as “ANAVEX PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually; and, has an anticipated ADAS-Cog improvement of about 4 points for the ANAVEX 2-73 mono-therapy and 7 points for ANAVEX PLUS in a humanized cortical network computer model.
TOP OFFICERS
|
Name
|
Title
|
Fiscal Year Pay
|
Biography
|
| Christopher Missling MS, PhD, MBA | Chairman, CEO | $240,000 | View Biography |
| Tasos Zografidis MS, PhD | VP of Clinical Operations | View Biography |
COMPANY NEWS
SHARE RELATED INFORMATION
| 52 Week High: | $1.64 on 8/19/15 | Total Shares Outstanding: | 77,243,500 |
| 52 Week Low: | .15 on 12/1/14 | Public Float: | 53,700,000 |
| All time High: | $5.39 on 12/31/07 | Earnings Per Share: | |
| All time Low: | .15 on 12/1/14 | Book Value: | .11 |
View Historical Stock Prices & Volume for this company
FUNDAMENTAL INVESTMENT HIGHLIGHTS
Stock is trading at a relative 52 week low and at an all time low on 12/1/14
Strong Balance Sheet, with approximately $7.3 million in cash on 12/1/14
Relatively low burn rate of approximately $330,000 per month, and enough cash to carry the company for approximately 1 and a half years
Recent private placement of $10 million is structured as a non interest bearing convertible note with a fixed conversion price of .30 a share
INSIDER ACTIVITY
N/A
FINANCIAL SNAPSHOT
|
All numbers in Thousands |
Fiscal Yr
Ends 9/2014 |
Prior Fiscal Yr
Ends 9/2013 |
Recent Quarter
Ends 3/2015 |
| Revenues | 0 | 0 | 0 |
| Pre-Tax Earnings (Losses) | ($2,969) | ($3,700) | ($1,725) |
| Total Cash | $7,262 | $345 | $6,310 |
| Total Assets | $7,353 | $393 | $6,364 |
| Total Liabilities | $2,969 | $2,856 | $1,662 |
| Shareholders Equity | $5,912 | ($2,463) | $4,702 |
View all Filings for this company
NEWSPAPER / MAGAZINE ARTICLES / RESEARCH REPORTS
|
Click here to go Back